ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we ...
A routine takeaway order led to a shocking medical emergency for 23-year-old medical student Alex Warwick, who suddenly ...
Victoria Gray spent 34 years battling the debilitating pain of sickle cell disease. Then she volunteered to be the world's first "prototype" for a CRISPR therapy, based on technology invented at UC ...
Many people are familiar with histamine, a biological molecule that serves as a key driver of allergic reactions and other ...
When scientists sent bacteria-infecting viruses to the International Space Station, the microbes did not behave the same way ...
A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...
Sometimes, in genetics, two wrongs do make a right. A research team has recently shown that two harmful genetic variants, ...
One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs that are initially effective lose their potency over time, as malignant ...
Live Science on MSN
These genes were thought to lead to blindness 100% of the time. They don't.
Genetic variants believed to cause blindness in nearly everyone who carries them actually lead to vision loss less than 30% ...
Validated clinical efficacy and scalable manufacturing propel exosomes from research discovery to commercial therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback